This product is a thromboxane (TX) synthase inhibitor, which can inhibit the generation of thromboxane A2 (TXA2) from prostaglandin H2 (PGH2), and promote the transfer of PGH2 derived from platelets to endothelial cells. Endothelial cells are used to synthesize PGI2, thereby improving the abnormal balance between TXA2 and prostaglandin PGI2. Theoretically, it can inhibit platelet aggregation and vasodilation. This product can improve movement disorders in the acute stage of cerebral thrombosis, improve circulatory disorders in the acute stage of cerebral ischemia, and improve abnormal energy metabolism during cerebral ischemia. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels, increase the ratio of 6-Keto-PGF1a/TXB2, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by middle cerebral artery occlusion in rats. The half-maximal inhibitory concentration IC50 of this product for human platelet aggregation is low, at 4nM. Experiments using autologous blood injected into the subarachnoid hemorrhage model showed that continuous intravenous injection of this product has the effects of inhibiting blood TXB2 concentration and cerebral vasoconstriction.

This product is a histamine H2 receptor blocker. It has a significant inhibitory effect on gastric acid secretion, and can also inhibit the secretion of pepsin, and has a certain protective effect on animal experimental ulcers. It takes effect about 1 hour after taking the medicine, and the effect can last for more than 12 hours.

It can antagonize histamine and acetylcholine, relieve bronchospasm and have an anti-asthmatic effect; it also has a strong inhibitory effect on the cough center; it can cause increased secretions, thin thick sputum, reduce sputum viscosity, and make it easier to cough up; it has a similar effect to aminophylline in relaxing bronchial smooth muscles; it can also increase the electrical stimulation valve of the cerebral cortex, inhibit the synaptic transmission of electrical stimulation and the spread of epileptic electricity.

No specific description of pharmacological effects is given from the above information

It can antagonize histamine and acetylcholine, relieve bronchospasm and have an anti-asthmatic effect; it has a strong inhibitory effect on the cough center; it can cause increased secretions, thin thick sputum, reduce sputum viscosity, and make it easier to cough up; it has a similar effect to aminophylline in relaxing bronchial smooth muscles; it can increase the electrical stimulation threshold of the cerebral cortex, inhibit the synaptic conduction of electrical stimulation and the spread of epileptic electricity.